Bruker Unveils Next-Generation Spatial Biology Portfolio

Bruker details new PaintScape and CellScape XR systems, expanded assays, and clinical partnerships, aiming to translate spatial biology innovation into revenue growth by 2026.

Bruker Corporation is accelerating the technological evolution of its spatial biology portfolio, presenting a detailed roadmap for platforms originally acquired from NanoString. The announcement, made at the AGBT 2026 conference, centers on new systems for 3D genome visualization and significant expansions to existing analytical capabilities. A key question for investors is the timeline for translating these advances into sustainable revenue growth for the company, which recently reported annual revenue of $3.44 billion.

Expanding Analytical Capabilities and Forging Clinical Partnerships

Alongside new hardware, Bruker is broadening the capacities of its CosMx and GeoMx platforms. A novel assay for the entire mouse transcriptome is entering an early-access program this spring, with a full commercial launch scheduled for late 2026. Furthermore, the company plans to introduce highly complex assays for miRNA and T-cell receptors. These will enable the simultaneous investigation of mRNA, proteins, and miRNA within the same single cell.

In proteomics, Bruker introduced the 'CellScape XR' system. Featuring enhanced optics and optimized data processing workflows, this platform is supported by a collaboration with the Proteintech Group for antibody labeling. Hardware updates for this system are slated for delivery in summer 2026.

These technological strides are being complemented by a clinical research partnership with the University of Glasgow. A new center of excellence for spatial biology will analyze over 1,000 samples from pancreatic cancer patients. The initiative aims to accelerate the translation of research findings into precision medicine applications.

A New Era in Genome Visualization

A cornerstone of the roadmap is the launch of the 'PaintScape' system. This platform is designed to visualize the spatial organization of the genome inside individual cells for the first time, allowing researchers to study structural variations directly within tissue. The system is now available for pre-order, with commercial shipments planned to commence in spring 2026.

Initially, the offering will include a panel for human cell lines. An expanded 'OncoPaint' panel, capable of profiling more than 1,000 target molecules simultaneously, is expected to follow later in the year. These innovations are primarily targeted at investigating gene dysregulation and its role in disease pathogenesis.

Software Advancements and Strategic Integration

To manage the complex datasets generated by these platforms, Bruker's AtoMx software is integrating new AI models for automated cell segmentation. These tools are intended to help researchers identify predictive biomarkers more rapidly and lower the barriers to complex data analysis.

The newly announced products represent core elements of the integration strategy following Bruker's acquisition of NanoString's assets in 2024. The first commercial deliveries of the PaintScape system in spring, followed by the CellScape XR market launch in summer 2026, are identified as the next key operational milestones for the corporation.